Oncology

1. In patients with advanced leiomyosarcoma, a regimen of doxorubicin-trabectedin was superior to doxorubicin alone in improving progression-free and overall...

1. In this randomized controlled trial, extended lymphadenectomy did not improve disease-free or overall survival in patients with muscle-invasive bladder...

1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group compared to chemotherapy alone. 2. Serious adverse...

1. Progression-free survival had a hazard ratio of 0.38 (extrapancreatic NETs) and 0.23 (pancreatic NETs) for those treated with cabozantinib...

1. Treatment of desmoid tumours with dual anti-CTLA-4 and anti-PD-1 blockade with ipilimumab and nivolumab resulted in an overall response...

1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse...

1. Ponsegromab at increasing doses resulted in a mean increase in body weight compared to placebo; 1.22 kg (2.21%) in...

1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug...

1. In a randomized double-blind placebo-controlled study, naldemedine use was associated with constipation prevention and a significant improvement of constipation-related...

1. In this cohort study, women were less likely to return for mammogram screening if their original result was a...